Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
Apolo, Andrea B, Ballman, Karla V, Sonpavde, Guru, Berg, Stephanie, Kim, William Y, Parikh, Rahul, Teo, Min Yuen, Sweis, Randy F, Geynisman, Daniel M, Grivas, Petros, Chatta, Gurkamal, Reichert, Zachery Roger, Kim, Joseph W, Bilen, Mehmet Asim, McGregor, Bradley, Singh, Parminder, Tripathi, Abhishek, Cole, Suzanne, Simon, Nicholas, Niglio, Scot, Ley, Lisa, Cordes, Lisa, Srinivas, Sandy, Huang, Jiaoti, Odegaard, Meagan, Watt, Colleen, Petrylak, Daniel, Hoffman-Censits, Jeannie, Wen, Yujia, Hahn, Olwen, Mitchell, Cecilia, Tan, Alan, Streicher, Howard, Sharon, Elad, Moon, Helen, Woods, Michael, Halabi, Susan, Perez Burbano, Gabriela, Morris, Michael J, Rosenberg, Jonathan E
Published in The New England journal of medicine (15.09.2024)
Published in The New England journal of medicine (15.09.2024)
Get more information
Journal Article
Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation
Apolo, Andrea B., Rosenberg, Jonathan E., Kim, William Y., Chen, Ronald C., Sonpavde, Guru, Srinivas, Sandy, Mortazavi, Amir, Watt, Colleen, Mallek, Marissa, Graap, Katherine, Diaz, Carlos, Odegaard, Meagan, Ballman, Karla V., Morris, Michael J.
Published in Journal of clinical oncology (01.03.2019)
Published in Journal of clinical oncology (01.03.2019)
Get full text
Journal Article